CN107698652A - 一种含丹参酮类化合物的吲哚胺2,3‑双加氧酶抑制剂 - Google Patents
一种含丹参酮类化合物的吲哚胺2,3‑双加氧酶抑制剂 Download PDFInfo
- Publication number
- CN107698652A CN107698652A CN201710900266.5A CN201710900266A CN107698652A CN 107698652 A CN107698652 A CN 107698652A CN 201710900266 A CN201710900266 A CN 201710900266A CN 107698652 A CN107698652 A CN 107698652A
- Authority
- CN
- China
- Prior art keywords
- tanshinone compound
- ido
- feature
- inhibitor containing
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N tanshinone IIA Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 title claims abstract description 36
- 229930183118 Tanshinone Natural products 0.000 title claims abstract description 32
- -1 tanshinone compound Chemical class 0.000 title claims abstract description 32
- 239000003112 inhibitor Substances 0.000 title claims abstract description 25
- 102000016680 Dioxygenases Human genes 0.000 title abstract description 4
- 108010028143 Dioxygenases Proteins 0.000 title abstract description 4
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 201000010099 disease Diseases 0.000 claims abstract description 17
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 13
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 13
- 230000037353 metabolic pathway Effects 0.000 claims abstract description 9
- 230000001575 pathological effect Effects 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims description 38
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 208000035473 Communicable disease Diseases 0.000 claims description 6
- 229910006069 SO3H Inorganic materials 0.000 claims description 6
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 208000002177 Cataract Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010017533 Fungal infection Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000031888 Mycoses Diseases 0.000 claims description 2
- 208000030852 Parasitic disease Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 210000002751 lymph Anatomy 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 229940113303 Indoleamine 2,3-dioxygenase inhibitor Drugs 0.000 abstract description 4
- 239000011149 active material Substances 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 description 20
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 8
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 5
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 240000007164 Salvia officinalis Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000000695 crystalline len Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 235000005412 red sage Nutrition 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- MUKYLHIZBOASDM-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid 2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound NC(=N)N(C)CC(O)=O.OCC(O)C(O)C(O)C(O)C(O)=O MUKYLHIZBOASDM-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000019800 Early-onset non-syndromic cataract Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 101710120843 Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000819233 Tribulus <sea snail> Species 0.000 description 1
- 239000004904 UV filter Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940047183 tribulus Drugs 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
- C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
- C07J73/003—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by oxygen as hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及吲哚胺2,3‑双加氧酶抑制剂技术领域，具体为一种以丹参酮类化合物为活性物质的吲哚胺2,3‑双加氧酶抑制剂。经IDO抑制活性检测，本发明所述结构的丹参酮类化合物或其药学上可接受的盐对于IDO具有抑制作用，其可对IDO在疾病发生发展中的促进作用进行阻碍和/或破坏，从而为治疗IDO介导的色氨酸代谢途径的病理学特征的疾病提供良好的前景。
Description
技术领域
本发明涉及吲哚胺2,3-双加氧酶抑制剂技术领域，尤其涉及一种以丹参酮类化合物为活性物质的吲哚胺2,3-双加氧酶抑制剂。
背景技术
吲哚胺2,3-双加氧酶(Indoleamine 2,3-dioxygenase,IDO)是一种细胞内含亚铁血红素的二聚体酶，控制着色氨酸沿犬尿氨酸代谢途径的关键限速步骤。在多种组织和细胞中均有表达，包括胎盘、肺、大肠、小肠、结肠、脾脏、肝脏、肾脏、胃、脑、肿瘤细胞、树突状细胞和巨噬细胞等。
IDO与众多疾病联系密切，在感染性疾病、癌症、神经相关类疾病以及白内障等疾病中，IDO的表达存在上调。在感染性疾病和癌症中，当出现炎症反应，一些生物因子，例如IFN-γ、NF-κB会诱导IDO基因的高表达，消耗更多的色氨酸，而T细胞对色氨酸缺乏的微环境较为敏感，在IDO诱导出的免疫抑制型抗原提呈细胞的影响下，T细胞停止增殖，并转变为抑制型调节T细胞，免疫反应受到抑制；色氨酸沿犬尿氨酸代谢的代谢终产物会对神经系统产生损伤，与阿尔茨海默病、帕金森病、亨廷顿舞蹈症等疾病联系密切；色氨酸也是五羟色胺的合成原料，五羟色胺的缺乏对抑郁症的产生至关重要；色氨酸降解的紫外线滤器化合物存在于人晶状体中，这些紫外线滤器化合物的量随年龄而增加,并且会导致与年龄相关的核性白内障的晶状体逐渐浑浊。IDO被认为是上述疾病的重要靶标，其抑制剂的发展具有广阔的应用前景。
目前尚未有批准上市的IDO抑制剂药物，IDO抑制剂的研发多处于实验室阶段，仅有三个抑制剂进入了临床试验。专利文献CN201610419113.4公开了如下结构的丹参酮IIA或其磺酸盐作为吲哚胺2,3-双加氧酶-1抑制剂的用途。
然而，由于化合物中的部分基团会显著影响其物理性质、化学性质及生物活性，即使骨架相似的化合物，其物理性质、化学性质及生物活性也可能存在巨大的差异。实验表明，丹参酮类化合物含6，7，8，9碳位的六元环与五元环上不同的取代基或双键对抑制吲哚胺2,3-双加氧酶的活性有显著影响，具体构效关系有待进一步研究。
丹参为唇形科鼠尾草属植物,为常用活血化瘀的中药。丹参酮为从丹参根部提取的脂溶性药用成分，临床上主要用于治疗冠心病、痤疮、痛经、失眠等病症。
发明内容
本发明的目的在于针对IDO被认为是许多疾病的重要靶标，而目前IDO抑制剂药物匮缺的问题，提供一种以丹参酮类化合物为活性物质的吲哚胺2,3-双加氧酶抑制剂，用于治疗或预防由吲哚胺2，3-双加氧酶介导的色氨酸代谢途径的病理学特征疾病。
为实现上述目的，本发明采用以下技术方案。
一种含丹参酮类化合物的吲哚胺2,3-双加氧酶抑制剂，所述抑制剂含有丹参酮类化合物和/或其药学上可接受的盐；所述丹参酮类化合物的结构式如下结构式A-G所示：
且当所述丹参酮类化合物的结构为结构式F时，R1不包括H，R2不包括H和SO3 -，R3不包括CH3。
优选的，上述结构的化合物中，R1为H、CH3、F、Cl、Br、I、OH、OCH3、NH2、NO2、CN、CHO、COOH、SH、SO3H或SO2H。
优选的，上述结构的化合物中，R2为H、R、F、Cl、Br、I、OH、OR、NH2、NHR、NR2、NO2、CN、CHO、COOH、COOR、COO-、SH、SR、SO3H、SO2R、SO3 -、SO2 -、SO2H或SO3R，其中的R是任意取代的饱和或不饱和的直链、支链或环状烃基基团或任意取代的芳基基团。
优选的，上述结构的化合物中，R3为H、CH3、F、Cl、Br、I、OH、OCH3、NH2、NO2、CN、CHO、COOH、SH、SO3H或SO2H。
更优选的，所述丹参酮类化合物为如下结构的化合物J1-J13：
以上所述的含丹参酮类化合物的吲哚胺2,3-双加氧酶抑制剂在制备治疗由吲哚胺2,3-双加氧酶介导的色氨酸代谢途径的病理学特征的疾病的药物中的应用，即可用于治疗由吲哚胺2,3-双加氧酶介导的色氨酸代谢途径的病理学特征的疾病。
所述由吲哚胺2,3-双加氧酶介导的色氨酸代谢途径的病理学特征的疾病包括癌症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、白内障、抑郁症和感染性疾病。
所述癌症包括卵巢癌、结直肠癌、肺癌、肝癌、肾癌、淋巴癌、胃癌、脑肿瘤和白血病。
所述感染性疾病包括细菌感染、真菌感染和寄生虫感染。
与现有技术相比，本发明的有益效果是：经IDO抑制活性检测，本发明所述结构的丹参酮类化合物或其药学上可接受的盐对于IDO具有抑制作用，其可对IDO在疾病发生发展中的促进作用进行阻碍和/或破坏，从而为治疗IDO介导的色氨酸代谢途径的病理学特征的疾病提供良好的前景。
具体实施方式
为了更充分的理解本发明的技术内容，下面结合具体实施例对本发明的技术方案作进一步介绍和说明。
分别测试评价丹参酮类化合物J1-J13及化合物K1-K7对吲哚胺2,3-双加氧酶的抑制活性。化合物K1-K7的结构分别如下所示。
化合物J1-J13及化合物K1-K7对吲哚胺2,3-双加氧酶的抑制活性的测试评价方法如下：
IDO酶学抑制试验
将90mL反应液加入96孔黑板，包括0.5M磷酸钾缓冲液10μL(pH6.5)、0.2M抗坏血酸10μL、0.5mM亚甲基蓝2μL、5mg/mL过氧化氢酶2μL、4mM L-色氨酸5μL、56μL超纯水以及不同浓度的待测化合物(化合物J1-J13，K1-K7)5μL。λex 360nm，λem 480nm条件下测量荧光值。反应液加入10μL 20μg/mL的IDO蛋白，37℃孵育1小时。20μL 1M NaOH溶液用以停止反应，60℃孵育15分钟。置于室温下冷却约1.5小时后同样条件下测量荧光值。阴性组和空白组以含1％DMSO的超纯水代替待测化合物溶液，空白组以0.05M磷酸钾缓冲液代替IDO蛋白溶液。不同抑制剂浓度下3次平行实验计算出IC50值。
抑制百分比＝100-(A/B×100)，A：有抑制剂条件下的IDO活性B：无抑制剂条件下的IDO活性。
化合物对吲哚胺2,3-双加氧酶的抑制活性的测试评价结果如下表1所示。
表1丹参酮类化合物在酶学抑制试验中的IC50值
从上表所示的测试结果可见，丹参酮类化合物含6，7，8，9碳位的六元环与五元环上不同的取代基或双键对抑制吲哚胺2,3-双加氧酶的活性有显著影响。当含6，7，8，9碳位的六元环上有双键或取代基时，可以显著提高丹参酮类化合物对IDO的抑制作用，如化合物J5、J6；五元环上的双键虽然不利于活性的提高，如化合物J1，但是其上的吸电子取代基对活性有提升作用，如化合物J8、J10；当五元环上的取代基为六元环甚至更大体积的基团时，其结构对活性影响较难预测，如化合物J12、J13、K6、K7。值得注意的是，本测试结果显示，化合物J1-J13的IDO抑制活性明显好于化合物K1(丹参酮IIA)的IDO抑制活性，化合物K1不具有良好的IDO抑制活性。
以下为部分化合物的结构表征：
化合物J12:HNMRδ:8.12-8.17(m,2H),7.76-7.79(m,2H),7.63(d,J＝8.1Hz,1H),7.56(m,J＝8.1Hz,1H),3.21(t,J＝6Hz,2H),2.25(s,3H),2.23(s,3H),1.76-1.85(m,2H),1.65-1.70(m,2H),1.33(s,6H)；MS m/z:467[M+1]+。
化合物J13:HNMRδ:8.14(m,2H),7.78(m,2H),7.63(d,J＝8.1Hz,1H),7.56(d,J＝8.1Hz,1H),3.21(t,J＝6.3Hz,2H),2.25(s,3H),2.23(s,3H),1.78-1.83(m,2H),1.61-1.66(m,2H),1.33(s,6H)；MS m/z:463[M-1]-。
化合物K4:HNMRδ:9.23(s,1H),8.97(s,1H),7.70(d,J＝8.1Hz,1H),7.45(d,J＝8.4Hz,1H),6.87(s,1H),6.83(d,J＝3.3Hz,1H),6.42(d,J＝3.3Hz,1H),2.22(s,3H),3.10(t,J＝6.3Hz,2H),1.78-1.83(m,2H),1.66-1.70(m,2H),1.29(s,6H)；CNMRδ:183.3,175.4,160.0,150.3,149.6,148.3,143.6,133.8,127.6,126.7,124.9,121.3,120.3,117.9,117.4,116.9,116.3,38.1,34.7,31.5,30.1,19.4,9.7；MS m/z:403[M+1]+。
化合物K5:HNMRδ:7.68(d,J＝8.1Hz,1H),7.17(d,J＝8.1Hz,1H),6.43(d,J＝8.7Hz,1H),6.87(s,1H),6.31(d,J＝8.7Hz,1H),3.21(t,J＝6.3Hz,2H),2.28(s,3H),1.78-1.85(m,2H),1.65-1.70(m,2H),1.34(s,6H)；CNMRδ:186.7,184.3,182.9,175.5,162.2,151.7,145.0,137.1,136.6,133.8,131.5,126.8,126.4,122.6,121.1,116.2,38.1,35.2,32.1,30.1,19.4,11.4；MS m/z:401[M+1]+。
化合物K6:MS m/z:453[M+1]+。
化合物K7:HNMRδ:8.12-8.15(m,1H),8.07-8.10(m,1H),7.76-7.79(m,2H),7.59(d,J＝8.1Hz,1H),7.65(d,J＝8.1Hz,1H),7.18(s,1H),3.18(t,J＝6Hz,2H),2.47(s,3H),1.77-1.83(m,2H),1.65-1.69(m,2H),1.33(s,6H)；CNMRδ:184.3,182.7,182.2,175.3,162.0,151.5,145.2,144.9,137.6,134.2,133.7,132.4,131.9,127.1,126.2,121.7,121.0,38.0,35.2,32.2,30.0,19.4,11.7；MS m/z:451[M+1]+。
以上所述仅以实施例来进一步说明本发明的技术内容，以便于读者更容易理解，但不代表本发明的实施方式仅限于此，任何依本发明所做的技术延伸或再创造，均受本发明的保护。
Claims (9)
1.一种含丹参酮类化合物的吲哚胺2,3-双加氧酶抑制剂，其特征在于，所述抑制剂含有丹参酮类化合物和/或其药学上可接受的盐；所述丹参酮类化合物的结构式如以下结构式A-G：
且当所述丹参酮类化合物的结构为结构式F时，R1不包括H，R2不包括H和SO3 -，R3不包括CH3。
2.根据权利要求1所述一种含丹参酮类化合物的吲哚胺2,3-双加氧酶抑制剂，其特征在于，所述R1为H、CH3、F、Cl、Br、I、OH、OCH3、NH2、NO2、CN、CHO、COOH、SH、SO3H或SO2H。
3.根据权利要求1所述一种含丹参酮类化合物的吲哚胺2,3-双加氧酶抑制剂，其特征在于，所述R2为H、R、F、Cl、Br、I、OH、OR、NH2、NHR、NR2、NO2、CN、CHO、COOH、COOR、COO-、SH、SR、SO3H、SO2R、SO3 -、SO2 -、SO2H或SO3R，其中的R是任意取代的饱和或不饱和的直链、支链或环状烃基基团或任意取代的芳基基团。
4.根据权利要求1所述一种含丹参酮类化合物的吲哚胺2,3-双加氧酶抑制剂，其特征在于，所述R3为H、CH3、F、Cl、Br、I、OH、OCH3、NH2、NO2、CN、CHO、COOH、SH、SO3H或SO2H。
5.根据权利要求1所述一种含丹参酮类化合物的吲哚胺2,3-双加氧酶抑制剂，其特征在于，所述丹参酮类化合物的结构式如以下结构式J1-J13：
6.根据权利要求1所述一种含丹参酮类化合物的吲哚胺2,3-双加氧酶抑制剂，其特征在于，在制备治疗由吲哚胺2,3-双加氧酶介导的色氨酸代谢途径的病理学特征的疾病的药物中的应用。
7.根据权利要求6所述一种含丹参酮类化合物的吲哚胺2,3-双加氧酶抑制剂，其特征在于，所述由吲哚胺2,3-双加氧酶介导的色氨酸代谢途径的病理学特征的疾病包括癌症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、白内障、抑郁症和感染性疾病。
8.根据权利要求7所述一种含丹参酮类化合物的吲哚胺2,3-双加氧酶抑制剂，其特征在于，所述癌症包括卵巢癌、结直肠癌、肺癌、肝癌、肾癌、淋巴癌、胃癌、脑肿瘤和白血病。
9.根据权利要求7所述一种含丹参酮类化合物的吲哚胺2,3-双加氧酶抑制剂，其特征在于，所述感染性疾病包括细菌感染、真菌感染和寄生虫感染。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710900266.5A CN107698652A (zh) | 2017-09-28 | 2017-09-28 | 一种含丹参酮类化合物的吲哚胺2,3‑双加氧酶抑制剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710900266.5A CN107698652A (zh) | 2017-09-28 | 2017-09-28 | 一种含丹参酮类化合物的吲哚胺2,3‑双加氧酶抑制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107698652A true CN107698652A (zh) | 2018-02-16 |
Family
ID=61175128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710900266.5A Pending CN107698652A (zh) | 2017-09-28 | 2017-09-28 | 一种含丹参酮类化合物的吲哚胺2,3‑双加氧酶抑制剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107698652A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109824753A (zh) * | 2018-11-20 | 2019-05-31 | 中国科学院昆明植物研究所 | 具有ido/tdo双选择性抑制活性的丹参酮iia衍生物 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102304166A (zh) * | 2011-07-02 | 2012-01-04 | 中国科学院昆明植物研究所 | 丹参酮衍生物，其药物组合物及其在制药中的应用 |
| CN102603861A (zh) * | 2012-02-25 | 2012-07-25 | 中国科学院昆明植物研究所 | 丹参酮衍生物及其药物组合物和其在医药中的用途 |
| CN103772478A (zh) * | 2013-12-30 | 2014-05-07 | 浙江大学 | 一种制备高纯度丹参酮化合物的单柱循环分离系统及其方法 |
| CN103193860B (zh) * | 2013-03-11 | 2016-01-27 | 常州大学 | 丹参酮类化合物、制备方法及其用途 |
| CN105884856A (zh) * | 2014-11-05 | 2016-08-24 | 中国药科大学 | 丹参酮ⅱa衍生物在医药中的应用 |
| CN106074570A (zh) * | 2016-06-13 | 2016-11-09 | 中山大学 | 丹参酮iia作为吲哚胺2,3‑双加氧酶‑1抑制剂的用途 |
-
2017
- 2017-09-28 CN CN201710900266.5A patent/CN107698652A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102304166A (zh) * | 2011-07-02 | 2012-01-04 | 中国科学院昆明植物研究所 | 丹参酮衍生物，其药物组合物及其在制药中的应用 |
| CN102603861A (zh) * | 2012-02-25 | 2012-07-25 | 中国科学院昆明植物研究所 | 丹参酮衍生物及其药物组合物和其在医药中的用途 |
| CN103193860B (zh) * | 2013-03-11 | 2016-01-27 | 常州大学 | 丹参酮类化合物、制备方法及其用途 |
| CN103772478A (zh) * | 2013-12-30 | 2014-05-07 | 浙江大学 | 一种制备高纯度丹参酮化合物的单柱循环分离系统及其方法 |
| CN105884856A (zh) * | 2014-11-05 | 2016-08-24 | 中国药科大学 | 丹参酮ⅱa衍生物在医药中的应用 |
| CN106074570A (zh) * | 2016-06-13 | 2016-11-09 | 中山大学 | 丹参酮iia作为吲哚胺2,3‑双加氧酶‑1抑制剂的用途 |
Non-Patent Citations (1)
| Title |
|---|
| 江城锋: "丹参酮类化合物结构修饰及其放射增敏活性的研究", 《中国优秀硕士学位论文全文数据库医药卫生科技辑》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109824753A (zh) * | 2018-11-20 | 2019-05-31 | 中国科学院昆明植物研究所 | 具有ido/tdo双选择性抑制活性的丹参酮iia衍生物 |
| CN109824753B (zh) * | 2018-11-20 | 2021-11-26 | 中国科学院昆明植物研究所 | 具有ido/tdo双选择性抑制活性的丹参酮iia衍生物 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Enhanced photodynamic therapy by reduced levels of intracellular glutathione obtained by employing a nano‐MOF with CuII as the active center | |
| Wang et al. | Cuprous oxide nanoparticles selectively induce apoptosis of tumor cells | |
| Lu et al. | Photosynthetic Oxygenation‐Augmented Sonodynamic Nanotherapy of Hypoxic Tumors | |
| Yang et al. | Design of the tumor microenvironment-multiresponsive nanoplatform for dual-targeting and photothermal imaging guided photothermal/photodynamic/chemodynamic cancer therapies with hypoxia improvement and GSH depletion | |
| Mandim et al. | Synthesis, photochemical and in vitro cytotoxic evaluation of new iodinated aminosquaraines as potential sensitizers for photodynamic therapy | |
| Perrone et al. | Bioactive phenolic compounds in the modulation of central and peripheral nervous system cancers: Facts and misdeeds | |
| Xie et al. | Novel PdPtCu Nanozymes for Reprogramming Tumor Microenvironment to Boost Immunotherapy Through Endoplasmic Reticulum Stress and Blocking IDO‐Mediated Immune Escape | |
| Chi et al. | Therapeutic and radiosensitizing effects of armillaridin on human esophageal cancer cells | |
| Justiniano et al. | The endogenous tryptophan‐derived photoproduct 6‐formylindolo [3, 2‐b] carbazole (FICZ) is a nanomolar photosensitizer that can be harnessed for the photodynamic elimination of skin cancer cells in vitro and in vivo | |
| CN107698652A (zh) | 一种含丹参酮类化合物的吲哚胺2,3‑双加氧酶抑制剂 | |
| Takahashi et al. | Antitumor effect of combination of hyperthermotherapy and 5-aminolevulinic acid (ALA) | |
| CN103833762A (zh) | 二氢卟吩类化合物、其制备方法、药物组合物和应用 | |
| Lee et al. | Adipocyte-targeting type I AIE photosensitizer for obesity treatment via photodynamic lipid peroxidation | |
| CN107759642A (zh) | 一种双糖基化苯并吩恶嗪类光敏剂及其制备方法和应用 | |
| Miao et al. | Aaptamine–a dual acetyl–and butyrylcholinesterase inhibitor as potential anti-Alzheimer’s disease agent | |
| Awale et al. | Targeting pancreatic cancer with novel plumbagin derivatives: Design, synthesis, molecular mechanism, in vitro and in vivo evaluation | |
| CN105777790B (zh) | 一种邻碳硼烷苯酚衍生物及其制备方法和应用 | |
| CN106749090A (zh) | 2‑（4‑羟基苯基）噻唑‑4‑羧酸乙酯衍生物的制备方法及其应用 | |
| CN107298648A (zh) | 一类大黄酸硫代酰胺类化合物、其制备方法及用途 | |
| CN105646476A (zh) | 联苯并[1,2,5]硒二唑衍生物及其制备方法和应用 | |
| Hirano et al. | Improvement of aminolevulinic acid (ALA)-mediated photodynamic diagnosis using n-propyl gallate | |
| Chu et al. | Detection and Elimination of Senescent Cells with a Self-Assembled Senescence-Associated β-Galactosidase-Activatable Nanophotosensitizer | |
| Ortel et al. | Adjuvants that empower the action of photodynamic therapy | |
| Batinic-Haberle | Mn-and Fe-porphyrin-based SOD mimics are powerful suppressors of itch in histamine-dependent and-independent mouse models | |
| Guleria et al. | PD26-04 A randomized study to compare outcomes of intravesical chemohyperthermia with mitomycin C vs intravesical BCG for intermediate and high risk NON-muscle invasive bladder cancer (NMIBC) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180216 |